Company or ticker...

BioTech

AbCellera Biologics

AbCellera Biologics advanced technology to quickly discover and develop antibody medicines by partnering with pharmaceutical companies, earning revenue from research fees, milestone payments, and royalties, while also building its own pipeline of drug candidates

Ticker

M. Cap

PS

PE

YTD

10MA

20MA

50MA

200MA

ABCL

1.1B

14.2

n/a

2.63%

Key Facts

M. Cap

PS

PE

YTD

1.1B

14.2

n/a

2.63%

10MA

20MA

50MA

200MA

$ABCL